Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/19/2026, 12:00:00 AM
Eli Lilly announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial on March 19, 2026, showing its next-generation 'Triple-G' agonist, retatrutide, led to significant reductions in A1C and body weight.
Korean Translation
2026년 3월 19일, 차세대 'Triple-G' 작용제인 레타트루타이드가 제2형 당뇨병 성인 환자의 당화혈색소(A1C)와 체중을 유의미하게 감소시켰다는 TRANSCEND-T2D-1 3상 임상시험의 긍정적인 탑라인 결과를 발표함.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
Schrodinger Inc (SDGR) · Earnings Release
First quarter 2026 earnings release scheduled. Analysts forecast an EPS of approximately -$0.56. As a major price catalyst, high importance is expected.
5/6/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is expected to report its Q1 2026 earnings, with analysts forecasting revenue of approximately $345.40M and a normalized EPS of -$0.19; medium impact expected from quarterly earnings release, scheduled.
5/5/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
Q1 2026 earnings release and conference call, with low importance estimated due to the routine nature of the announcement, scheduled.
5/5/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q1 2026 earnings release is scheduled; major tech earnings typically cause >=5% price impact, justifying a Medium importance estimate.
4/23/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's first-quarter 2026 earnings release is scheduled. I estimate Medium importance as earnings reports typically cause significant price movement, so the event is scheduled.
4/21/2026, 12:00:00 AM